Zhongzhi Pharmaceutical Holdings Ltd. held its Annual General Meeting on 13 May 2025. During the meeting, several proposals were presented and approved. These included the approval of the audited consolidated financial statements and the reports of the directors and the auditor for the year ended 31 December 2024, as well as the declaration and payment of a final dividend of HK5 cents per ordinary share. Additionally, Mr. Lai Ying Feng was re-elected as an executive director of the company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.